AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...

USA-based Madrigal Pharmaceuticals today announced that it has entered into an exclusive global license agreement with CSPC ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

AstraZeneca, a pharmaceutical company, has announced its plans to bring a drug substance manufacturing facility to Virginia.

DelveInsight’s Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ ...

AstraZeneca to spend $50 billion in US production build out to avert tariff threat Texas, Virginia, Indiana and Massachusetts are all part of the drugmaker’s plans.

AstraZeneca to build largest US plant in Virginia as part of $50B investment in US President Donald Trump referenced the announcement the following day in Oval Office remarks, framing AstraZeneca’s ...

International firms are also looking to partner with Chinese counterparts at earlier stages to co-develop drugs – such as ...

AstraZeneca Short Interest Graph (3 Months) As you can see from the chart above the percentage of shares that are sold short for AstraZeneca has declined since its last report.